Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTRZQE3)

• DTT Name: Glycogen synthase kinase-3 alpha (GSK-3A) DTT Info
• UniProt ID: GSK3A_HUMAN
• Gene Name: GSK3A

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[1], [2]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lithium	DMZ3OU6	Fragile X syndrome	LD55	Phase 2	[3]
LY2090314	DMTBFE4	Acute myeloid leukaemia	2A60	Phase 2	[4], [5]

29 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR-A014418	DMUPN01	Ovarian cancer	2C73	Patented	[4]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[4]
Indazole derivative 6	DMGO1CB	N. A.	N. A.	Patented	[4]
Indirubin derivative 2	DMLX183	N. A.	N. A.	Patented	[4]
KENPAULLONE	DMAGVXW	Discovery agent	N.A.	Patented	[4]
Maleimides derivative 1	DMINM8F	N. A.	N. A.	Patented	[4]
Maleimides derivative 2	DMUVYWE	N. A.	N. A.	Patented	[4]
Maleimides derivative 3	DMEFQND	N. A.	N. A.	Patented	[4]
N-naphtyl-N-benzylurea derivative 1	DMCVBPF	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-15	DM3G21F	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-16	DM9VXY7	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-17	DMR7V9E	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-18	DMNR6KL	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-19	DM8V7QH	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-20	DMDA3PN	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-21	DMO1NAR	N. A.	N. A.	Patented	[4]
PMID27828716-Compound-BIO-acetoxime	DMUM5L6	Malignant glioma	2A00.0	Patented	[4]
Pyrazole and benzimidazole derivative 1	DM05S2X	N. A.	N. A.	Patented	[4]
Pyrazolodihydropyridine derivative 1	DMKYX7J	N. A.	N. A.	Patented	[4]
Quinoline derivative 14	DMSRB8M	N. A.	N. A.	Patented	[4]
Quinoline derivative 15	DM7HD0T	N. A.	N. A.	Patented	[4]
Quinolinyl pyrazinyl urea derivative 1	DMCIKR3	N. A.	N. A.	Patented	[4]
Quinolinyl pyrazinyl urea derivative 2	DMKJN9G	N. A.	N. A.	Patented	[4]
Spiroquinolone derivative 1	DMYJL2Z	N. A.	N. A.	Patented	[4]
TDZD-8	DMG6Q45	Malignant glioma	2A00.0	Patented	[4]
Thiadiazolidindione derivative 1	DM1L3ZA	N. A.	N. A.	Patented	[4]
Thiadiazolidindione derivative 2	DM5AUL0	N. A.	N. A.	Patented	[4]
Thiadiazolidindione derivative 3	DMNTZ93	N. A.	N. A.	Patented	[4]
Tricyclic 5-quinolone derivative 1	DMYEDJI	N. A.	N. A.	Patented	[4]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
6-bromoindirubin-3-oxime	DM12WYV	Discovery agent	N.A.	Investigative	[6]
AR-534	DMNJ632	Discovery agent	N.A.	Investigative	[7]
Benzofuran-3-yl-(indol-3-yl)maleimides	DMNVG1M	Discovery agent	N.A.	Investigative	[8]
Lithium chloride	DMHYLQ2	Discovery agent	N.A.	Investigative	[9], [10]
SB216763	DMIYFQ5	Discovery agent	N.A.	Investigative	[11], [12], [13]

References

• [1] Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
• [2] Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
• [3] The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
• [4] Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
• [5] Activating the Wnt/beta-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.
• [6] Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis. 2009 Jun;47(6):414-22.
• [7] A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest. 2009 May;119(5):1382-95.
• [8] From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63.
• [9] Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
• [10] Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002 Mar;8(3):126-32.
• [11] Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149 Suppl 1:45-50.
• [12] Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology. 2009 Jun;56(8):1116-23.
• [13] The ceiling effect of pharmacological postconditioning with the phytoestrogen genistein is reversed by the GSK3beta inhibitor SB 216763 [3-(2,4-dic... J Pharmacol Exp Ther. 2009 Jun;329(3):1134-41.